Position in BIIB
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$123,364,642
+$18,578,531 QoQ
Shares Held
570,974
-0.1% QoQ
Ownership
0.387%
of shares outstanding
% of Portfolio
1.10%
of 13F equity value
Holder Rank
#39
of 1,036 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Artemis Investment Management LLP holds $978,265,315 across 7 Drug Manufacturers - General names. BIIB ranks #4 (12.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
1,279,269 | $242,574,987 | |
| 2 | PFE |
Pfizer Inc
|
7,612,597 | $183,311,335 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
3,053,480 | $175,941,517 | |
| 4 | BIIB |
Biogen Inc.
This page
|
570,974 | $123,364,642 | |
| 5 | ABBV |
AbbVie Inc.
|
482,591 | $121,439,199 | |
| 6 | LLY |
ELI LILLY & Co
|
95,948 | $115,082,919 | |
| 7 | JNJ |
Johnson & Johnson
|
65,168 | $16,550,716 |
All Filings in BIIB
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $123,364,642 | 570,974 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $104,786,111 | 571,571 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $39,922,451 | 226,845 | Shares | Sole | 2026-02-02 | |
| 2022-09-30 | $5,626,758 | 21,074 | Shares | Sole | 2022-10-25 | |
| 2020-06-30 | $5,668,314 | 21,186 | Shares | Sole | 2020-07-27 | |
| 2020-03-31 | $14,006,775 | 44,272 | Shares | Sole | 2020-04-14 | |
| No filing history on record for this holder in this stock. | ||||||